S-1: Imunon Faces Imminent Nasdaq Delisting Amidst Financial Distress and Capital Raise Efforts

Imunon, a clinical-stage biotechnology company, is registering shares for resale by existing investors following a private placement, while simultaneously grappling with severe financial challenges, including multiple Nasdaq delisting notices and substantial doubt about its ability to continue as a going concern.

Summary

• Imunon, Inc. has filed an S-1 registration statement for the resale of up to 22,027,780 shares of common stock by selling securityholders.
• The shares include 2,777,779 common shares, 4,444,444 shares issuable from pre-funded warrants, 14,444,446 shares from common warrants, and 361,111 shares from placement agent warrants.
• The underlying private placement closed on May 27, 2025, at a combined purchase price of $0.45 per share and accompanying warrant.
• The company will not receive proceeds from the resale of shares by selling securityholders, but could receive approximately $6.7 million if all common and placement agent warrants are exercised for cash.
• Imunon reported a net loss of $4.1 million for the quarter ended March 31, 2025, and $18.6 million for the year ended December 31, 2024.
• Cash and cash equivalents stood at $2.9 million as of March 31, 2025, down from $5.9 million at December 31, 2024.
• The company has accumulated approximately $411 million in net losses as of March 31, 2025.
• Imunon received a Nasdaq delisting notice on May 28, 2025, for failing to meet the minimum $1.00 bid price requirement by the May 27, 2025 deadline, and has requested an appeal.
• Additionally, on May 19, 2025, Nasdaq notified the company of non-compliance with the minimum stockholders' equity requirement ($2.5 million), with a deadline of July 3, 2025, to submit a compliance plan.
• The company's independent registered public accounting firm included a going concern explanatory paragraph in its report for the year ended December 31, 2024, indicating insufficient cash to operate for at least one year without additional funding.
• Imunon's lead clinical program, IMNN-001 for advanced ovarian cancer, has finalized its Phase 3 study design (OVATION 3) with FDA alignment, and positive Phase 2 data (OVATION 2) was announced on May 23, 2025.
• The company also completed a first-in-human study for its COVID-19 booster vaccine, IMNN-101.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to severe financial distress, including a 'going concern' warning from auditors, critically low cash reserves, and two active Nasdaq delisting notices. While there are positive clinical trial updates, the existential financial and listing risks overshadow any operational progress, indicating a highly precarious situation for investors.

Positives

• Imunon has finalized the Phase 3 study design for its lead candidate, IMNN-001, for advanced ovarian cancer, with alignment from the U.S. Food and Drug Administration (FDA).
• New positive data from the Phase 2 OVATION 2 Study of IMNN-001 for advanced ovarian cancer was announced on May 23, 2025.
• The company has completed a first-in-human study of its COVID-19 booster vaccine, IMNN-101, demonstrating progress in its PlaCCine modality.
• The private placement, which closed on May 27, 2025, provides a mechanism for potential future capital infusion of approximately $6.7 million if all associated warrants are exercised for cash.

Negatives

• Imunon received a delisting notice from Nasdaq on May 28, 2025, for failing to meet the minimum $1.00 bid price requirement, and there is no assurance the appeal will be granted.
• The company also received a Nasdaq notice on May 19, 2025, for non-compliance with the minimum stockholders' equity requirement ($2.5 million), reporting equity below this threshold as of March 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern, as indicated by its independent auditors and management, due to significant net losses and low cash reserves.
• The company incurred a net loss of $4.1 million in Q1 2025 and $18.6 million in FY 2024, with cumulative net losses reaching approximately $411 million.
• Cash and cash equivalents have significantly decreased from $5.9 million at December 31, 2024, to $2.9 million at March 31, 2025.
• The company will not receive any proceeds from the current resale of shares by selling securityholders, limiting immediate capital infusion from this offering.
• The exercisability of a significant portion of warrants (Common Warrants and Placement Agent Warrants) is contingent upon obtaining Stockholder Approval, which if not received, would render these warrants valueless.

Risks

• The sale or availability for sale of shares by selling securityholders may depress the price of the Common Stock and dilute existing stockholders' interests.
• The company's Common Stock may be delisted from Nasdaq if it fails to comply with continued listing standards, which could severely limit liquidity and ability to raise capital.
• Delisting could result in the Common Stock becoming a 'penny stock,' further affecting market liquidity and investor ability to trade.
• The company will need to raise significant additional capital to fund future operations, and there is no assurance it can secure such capital on favorable terms or at all, potentially jeopardizing its ability to continue as a going concern.
• The inherent uncertainty in the drug development process means there is no guarantee that clinical trials will be completed successfully or that drug candidates will obtain regulatory approvals.
• The company has never paid dividends and does not anticipate doing so in the foreseeable future, meaning capital appreciation is the sole source of potential gain for investors.
• The company's ability to obtain Stockholder Approval for the exercisability of Common Warrants and Placement Agent Warrants is uncertain, and failure to do so would render these warrants valueless.

Future Outlook

Imunon plans to continue advancing its non-viral DNA technology across its TheraPlas and PlaCCine modalities, either directly or through partnerships. The company intends to proceed with the Phase 3 registrational trial (OVATION 3) for IMNN-001 in advanced ovarian cancer, having finalized the study design and received FDA alignment. Management acknowledges the need to raise significant additional capital to fund planned future operations, including research and development, preclinical studies, clinical trials, and potential manufacturing and commercialization activities. The company is evaluating options to regain compliance with Nasdaq listing standards and intends to timely submit a plan for the minimum stockholders' equity requirement.

Management Comments

• "We are currently evaluating options to regain compliance and intend to timely submit a plan to regain compliance with the minimum stockholders equity requirement."
• "Although the Company intends to use all reasonable efforts to achieve compliance with the minimum stockholders equity requirement, there can be no assurance that the Company will be able to regain compliance with the minimum stockholders equity requirement or that the Company will otherwise be in compliance with other applicable Nasdaq listing criteria."
• "There can be no assurance the Staff will grant our request for continued listing [on Nasdaq]."

Industry Context

Imunon operates in the highly competitive and regulated clinical-stage biotechnology sector, focusing on innovative DNA-based immunotherapies for solid tumors (TheraPlas) and infectious diseases (PlaCCine). The development of IMNN-001 for advanced ovarian cancer places it in a challenging oncology market, where novel immunotherapies are highly sought after but face significant development hurdles and high capital requirements. The progress with IMNN-001's Phase 3 design and positive Phase 2 data are critical milestones in this space. Similarly, the PlaCCine platform for vaccines, exemplified by the COVID-19 booster, positions Imunon in the dynamic infectious disease vaccine market, which has seen accelerated development and investment post-pandemic. However, the company's severe financial distress and delisting risks are significant headwinds, contrasting with the capital-intensive nature of drug development and the need for sustained funding to compete effectively.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess Imunon's performance against global industry benchmarks. The focus is on the company's internal financial state and clinical development progress.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from the large number of shares registered for resale and potential future capital raises. The ongoing Nasdaq delisting issues pose a severe threat to liquidity and the value of their investment. The 'going concern' doubt indicates a high risk of losing most or all of their investment.
• **Employees**: The company's precarious financial position and 'going concern' doubt could lead to job insecurity or operational restructuring.
• **Creditors**: The 'going concern' doubt and low cash reserves increase the risk for creditors regarding the company's ability to meet its financial obligations.
• **Patients/Medical Community**: Progress in clinical trials for IMNN-001 and IMNN-101 offers potential future benefits, but the company's financial instability could jeopardize the continued development and eventual availability of these treatments.

Next Steps

• Hold a stockholder meeting on or prior to August 25, 2025, to obtain Stockholder Approval for the exercisability of Common Warrants and Placement Agent Warrants.
• File a proxy statement for the stockholder meeting by June 16, 2025.
• If Stockholder Approval is not obtained at the first meeting, call a meeting every 90 days thereafter until approval is secured or warrants are no longer outstanding.
• Submit a plan to Nasdaq by July 3, 2025, to regain compliance with the minimum stockholders' equity requirement.
• Pursue an appeal with a Nasdaq Hearings Panel regarding the delisting notice for the minimum bid price requirement.
• Evaluate options and use reasonable efforts to regain compliance with all Nasdaq listing standards.
• Raise additional capital to fund planned future operations, including research and development activities and the Phase 3 registrational trial of IMNN-001.

Key Dates

Recommendation

Keywords

Imunon, Biotechnology, SEC Filing, S-1 Registration, Common Stock, Warrants, Private Placement, Nasdaq Delisting, Going Concern, Ovarian Cancer, IMNN-001, Clinical Trials, TheraPlas, PlaCCine, Vaccine Development, Financial Health, Capital Raise, Share Dilution